Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Advanced Malignancies
Interventions: Part A, Part B; Biological
Lead sponsor: TopAlliance Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Brain and Central Nervous System Tumors
Interventions: cintredekin besudotox, isolated perfusion, conventional surgery; Biological · Drug · Procedure
Lead sponsor: New Approaches to Brain Tumor Therapy Consortium; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more

Conditions: Advanced Solid Tumor
Interventions: HLX23; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Orange City, Florida + 3 more

Conditions: Neoplasms, Breast
Interventions: lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 8
States / cities: Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more

Conditions: Community-Acquired Bacterial Pneumonia
Interventions: Levofloxacin, CEM-101; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more

Conditions: Ovarian Cancer
Interventions: cisplatin, paclitaxel, conventional surgery; Drug · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 47 more

Conditions: Chest Pain, Coronary Occlusion, Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: Not listed
Enrollment: 42,926 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 50
States / cities: Ann Arbor, Michigan • Bay City, Michigan • Commerce, Michigan + 36 more

Conditions: Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions: Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 154
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) 2009 monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more

Conditions: Ischemia-Reperfusion Injury
Interventions: autoRIC, autoRIC Sham; Device
Lead sponsor: CellAegis US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Danbury, Connecticut • Jacksonville, Florida + 10 more

Conditions: Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
Interventions: ADU-1805, Pembrolizumab; Drug
Lead sponsor: Sairopa B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • St Louis, Missouri • Charlotte, North Carolina + 5 more

Conditions: Mitral Valve Disease
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Hepatitis C
Interventions: CTS-1027, pegylated interferon, Ribavirin, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more

Conditions: HIV Infection
Interventions: Emtricitabine/tenofovir disoproxil; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 80
States / cities: Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more

Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Interventions: SBP-101, Nab-paclitaxel, Gemcitabine, Placebo; Drug · Other
Lead sponsor: Panbela Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 23 more

Conditions: Breast Cancer
Interventions: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography; Device
Lead sponsor: U-Systems, Inc.; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 15,679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more

Conditions: Glioblastoma
Interventions: Bevacizumab, Onartuzumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
Interventions: Eflornithine (Dose Level -1), Eflornithine (Dose Level 2), Temozolomide; Drug
Lead sponsor: Orbus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more

Conditions: Pain
Interventions: Adductor Canal Block, Periarticular Injection, Ropivacaine, Bupivacaine; Procedure · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atrial Fibrillation, Stroke
Interventions: CLAAS, WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder; Device
Lead sponsor: Conformal Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Search by objective public record fields.

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Immunotoxin Therapy in Treating Patients With Malignant Glioma

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Advanced Cardiovascular Imaging Consortium

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

Remote Ischemic Conditioning Using the autoRIC

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Mitral Valve Screening Survey

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Factors Affecting PrEP Adherence

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?

The CONFORM Pivotal Trial